LIPOSOMFORMULIERUNGEN

European patent · EP2887958 · In force

Register entry

Publication number
EP2887958
Application number
EP13830622
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Aug 15, 2013
Published
Jul 1, 2015
Granted
May 19, 2021
Protection ends at the latest
Aug 14, 2033
Next annual fee due
Aug 31, 2027
IPC classes
A61K 9/127 (2006.01)
A61K 31/58 (2006.01)
A61K 39/395 (2006.01)
A61K 39/00 (2006.01)
Priority
US 201261691455 P 21.08.2012
US 201361791693 P 15.03.2013
US 201361862300 P 05.08.2013
PCT application
PCT/US2013/055084 15.08.2013
PCT publication
WO2014/031429 27.02.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 1, 2026

    Next annual fee due on

    Next annual fee due on
    31.08.2026 → 31.08.2027

    Published in Swissreg on 01.09.2026

  2. Sep 1, 2025

    Next annual fee due on

    Next annual fee due on
    31.08.2025 → 31.08.2026

    Published in Swissreg on 01.09.2025

  3. Sep 3, 2024

    Next annual fee due on

    Next annual fee due on
    31.08.2024 → 31.08.2025

    Published in Swissreg on 03.09.2024

  4. Sep 1, 2023

    Change

    Published in Swissreg on 01.09.2023

  5. Sep 6, 2022

    Change

    Published in Swissreg on 06.09.2022

  6. Mar 30, 2022

    Change

    Published in Swissreg on 30.03.2022

  7. May 19, 2021

    Granted

    Published in Swissreg on 19.05.2021

Parties

Holder

OPKO Pharmaceuticals, LLC

4400 Biscayne Boulevard, Miami, FL 33137, US

Inventor

FROST, Phillip

Miami Beach Florida 33139, US

SANTOS, Arturo

45116 Zapopán, MX

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.